Search research articles
Contact Us
Filters
Showing results (31-40 of 44) with videos related to
Page
of 5
Sort By:
Multiple Sclerosis and Related Disorders
|
June 21, 2023
Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study
Wallace J Brownlee, Aiden Haghikia, Brooke Hayward, et al.
Reproductive Biomedicine Online
|
April 9, 2024
Effectiveness of recombinant human FSH: recombinant human LH combination treatment versus recombinant human FSH alone for assisted reproductive technology in women aged 35-40 years
Alexandra P Bielfeld, Juan-Enrique Schwarze, Patrice Verpillat, et al.
Therapeutic Advances in Neurological Disorders
|
May 6, 2015
A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing-remitting multiple sclerosis
Robert Zivadinov, Michael Dwyer, Silva Markovic-Plese, et al.
Neurodegenerative Disease Management
|
February 1, 2021
CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis
Augusto A Miravalle, Joshua Katz, Derrick Robertson, et al.
Journal of Neuroimmunology
|
April 14, 2015
Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing-remitting multiple sclerosis over 24 weeks of therapy with subcutaneous interferon beta-1a three times weekly
Michael G Dwyer, Robert Zivadinov, Silva Markovic-Plese, et al.
Plos One
|
March 15, 2014
Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study
Robert Zivadinov, Michael G Dwyer, Silva Markovic-Plese, et al.
AIDS Research and Human Retroviruses
|
March 14, 2024
Incident HIV-Associated Wasting/Low Weight Is Associated with Nearly Doubled Mortality Risk in the Modern ART Era
Michael B Wohlfeiler, Rachel Palmieri Weber, Laurence Brunet, et al.
AIDS Research and Human Retroviruses
|
July 25, 2023
Definition, Burden, and Predictors of HIV-Associated Wasting and Low Weight in the OPERA Cohort
Michael B Wohlfeiler, Rachel Palmieri Weber, Laurence Brunet, et al.
Neurology(R) Neuroimmunology & Neuroinflammation
|
November 25, 2015
Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS
Yazhong Tao, Xin Zhang, Robert Zivadinov, et al.
BMC Neurology
|
November 13, 2015
Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial
Michael G Dwyer, Robert Zivadinov, Yazhong Tao, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 44) with videos related to
Sort By:
Page
of 5
Multiple Sclerosis and Related Disorders
|
June 21, 2023
Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study
Wallace J Brownlee, Aiden Haghikia, Brooke Hayward, et al.
Reproductive Biomedicine Online
|
April 9, 2024
Effectiveness of recombinant human FSH: recombinant human LH combination treatment versus recombinant human FSH alone for assisted reproductive technology in women aged 35-40 years
Alexandra P Bielfeld, Juan-Enrique Schwarze, Patrice Verpillat, et al.
Therapeutic Advances in Neurological Disorders
|
May 6, 2015
A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing-remitting multiple sclerosis
Robert Zivadinov, Michael Dwyer, Silva Markovic-Plese, et al.
Neurodegenerative Disease Management
|
February 1, 2021
CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis
Augusto A Miravalle, Joshua Katz, Derrick Robertson, et al.
Journal of Neuroimmunology
|
April 14, 2015
Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing-remitting multiple sclerosis over 24 weeks of therapy with subcutaneous interferon beta-1a three times weekly
Michael G Dwyer, Robert Zivadinov, Silva Markovic-Plese, et al.
Plos One
|
March 15, 2014
Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study
Robert Zivadinov, Michael G Dwyer, Silva Markovic-Plese, et al.
AIDS Research and Human Retroviruses
|
March 14, 2024
Incident HIV-Associated Wasting/Low Weight Is Associated with Nearly Doubled Mortality Risk in the Modern ART Era
Michael B Wohlfeiler, Rachel Palmieri Weber, Laurence Brunet, et al.
AIDS Research and Human Retroviruses
|
July 25, 2023
Definition, Burden, and Predictors of HIV-Associated Wasting and Low Weight in the OPERA Cohort
Michael B Wohlfeiler, Rachel Palmieri Weber, Laurence Brunet, et al.
Neurology(R) Neuroimmunology & Neuroinflammation
|
November 25, 2015
Immunologic and MRI markers of the therapeutic effect of IFN-β-1a in relapsing-remitting MS
Yazhong Tao, Xin Zhang, Robert Zivadinov, et al.
BMC Neurology
|
November 13, 2015
Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial
Michael G Dwyer, Robert Zivadinov, Yazhong Tao, et al.
Page
of 5